Prion disease detected soon after infection and in surprising place in mouse brains
Scientists believe prion diseases potentially could be treated if therapy starts early in the disease cycle. However, identifying who needs treatment and pinpointing the optimal timeframe for treatment are open questions for researchers.
Human prion diseases include variant, familial and sporadic Creutzfeldt-Jakob disease (CJD). The most common form, sporadic CJD, affects an estimated one in one million people annually worldwide. Other prion diseases include scrapie in sheep, chronic wasting disease in deer, elk and moose, and bovine spongiform encephalopathy in cattle.
In their study, the NIAID scientists injected infectious scrapie prion protein into the brains of mice. After 30 minutes, they began observing whether the injected material generated new infectious protein at the injection site. By examining mouse brain tissue, the researchers measured and detected new infectious prion protein three days after infection on the outside walls of capillaries and other blood vessels at the injection site. Using Real-Time Quaking-Induced Conversion (RT-QuIC), a feasible testing method for people, the scientists detected newly generated prion protein after seven days. In prior studies, it took about six weeks to detect infectious prion protein. The new findings enhance scientific understanding of where infectious prion diseases might take hold in the brain and provide possible targets for treatment.
Original publication
Bruce Chesebro, James Striebel, Alejandra Rangel, Katie Phillips, Andrew Hughson, Byron Caughey, Brent Race; "Early Generation of New PrPSc on Blood Vessels after Brain Microinjection of Scrapie in Mice"; mBio; 2015
Most read news
Original publication
Bruce Chesebro, James Striebel, Alejandra Rangel, Katie Phillips, Andrew Hughson, Byron Caughey, Brent Race; "Early Generation of New PrPSc on Blood Vessels after Brain Microinjection of Scrapie in Mice"; mBio; 2015
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.